Interventional Oncology Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Embolization Devices, Ablation Devices, Support Devices), By Procedure (Thermal Tumour Ablation, Non-thermal Tumour Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE), Transcatheter Arterial Embolization (TAE)), By Cancer Type (Liver, Kidney, Lung, Bone, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Interventional Oncology Devices Market, valued at USD 2.74 Billion in 2024, is projected to experience a CAGR of 7.90% to reach USD 4.32 Billion by 2030. Interventional oncology devices represent specialized medical instrumentation employed in image-guided, minimally invasive procedures for the diagnosis, treatment, and palliation of various cancers. The market's expansion is fundamentally driven by the increasing global prevalence of cancer and a growing preference for less invasive therapeutic interventions, which offer advantages such as reduced recovery times and fewer complications. According to the World Health Organization and the International Agency for Research on Cancer, approximately 20 million new cancer cases were diagnosed globally in 2022, indicating a substantial patient population requiring advanced oncology solutions.

Furthermore, continuous technological advancements in imaging and therapeutic modalities contribute significantly to market growth. However, a notable challenge impeding market expansion remains the limited availability of adequately trained interventional oncologists and the substantial procedural costs associated with these advanced treatment modalities.

Key Market Drivers

The increasing global cancer incidence is a significant catalyst for the interventional oncology devices market, generating an expanding patient demographic in need of advanced diagnostic and treatment modalities. The rising number of new cancer diagnoses globally creates a fundamental demand for minimally invasive, image-guided interventions that offer targeted therapy with reduced systemic impact. For example, according to the "Global Cancer Statistics, 2024" report published by the American Cancer Society and the International Agency for Research on Cancer on April 4, 2024, lung cancer was the most frequently diagnosed cancer in 2022, accounting for 2.5 million new cases worldwide, underscoring the substantial and ongoing demand for specialized oncology solutions. This growing burden necessitates a wider array of effective and less invasive tools, directly stimulating the development and adoption of interventional oncology devices.

Complementing this demand is the continuous stream of technological advancements in devices and imaging, which directly enhances the precision, efficacy, and safety of interventional oncology procedures. These innovations enable interventional oncologists to perform more complex treatments with greater accuracy, improving patient outcomes and expanding the applicability of these therapies to a broader range of cancer types and stages. A notable development includes AngioDynamics, Inc. announcing on December 9, 2024, that it received U. S. Food and Drug Administration 510(k) clearance for its NanoKnife System for prostate tissue ablation, demonstrating ongoing innovation in targeted device technology. Such advancements foster greater clinical confidence and patient acceptance, driving market growth. Reflecting the tangible impact of these advancements and the market's activity, the pivotal PRESERVE clinical study for the AngioDynamics NanoKnife System, evaluating prostate tissue ablation, enrolled 121 patients across 17 clinical sites. This collective progress underscores the dynamic evolution and expansion of the global interventional oncology devices landscape.

Download Free Sample Report

Key Market Challenges

A notable challenge impeding market expansion is the limited availability of adequately trained interventional oncologists. These specialized medical procedures necessitate a high degree of expertise in image-guided, minimally invasive techniques, making the presence of skilled professionals critical for the adoption and utilization of associated devices. A deficiency in this expert workforce directly restricts the number of procedures that can be performed, thereby hampering the overall demand for interventional oncology instruments.

This scarcity limits patient access to advanced therapeutic interventions and constrains the market's growth potential. For instance, according to The Royal College of Radiologists' Clinical Radiology Workforce Census 2023, published in June 2024, only 48% of UK trusts and health boards were able to provide an adequate interventional radiology service. Such workforce shortfalls mean that even as device technology advances and the global cancer burden increases, the market cannot fully capitalize on these opportunities due to an insufficient number of practitioners capable of delivering these complex treatments.

Key Market Trends

Artificial Intelligence and Machine Learning Integration for Precision marks a significant trend in the Global Interventional Oncology Devices Market by refining diagnostic accuracy and therapeutic targeting. The application of sophisticated algorithms allows for the analysis of complex patient data, including genomics and imaging, to guide more precise interventions. According to a EuroAIM/EuSoMII 2024 survey, nearly 48% of European Society of Radiology members are currently using AI systems in their clinical practice, indicating a notable adoption rate within a directly relevant medical specialty. This integration facilitates optimized treatment pathways and improved patient stratification. For instance, in April 2025, Tempus announced a partnership with Pfizer to utilize AI for clinical trial patient matching in oncology, demonstrating how AI enhances the development and application of personalized cancer therapies.

The Expansion of Outpatient and Ambulatory Surgical Centers represents another pivotal trend, shifting interventional oncology procedures from traditional hospital settings to more cost-effective and patient-centric environments. This migration is driven by advancements in minimally invasive techniques and evolving healthcare policies, offering advantages such as reduced recovery times and lower overheads. According to a March 2025 report by MedPAC, the number of Medicare-certified Ambulatory Surgical Centers increased by 2.5 percent to 6,308 facilities in 2023, highlighting consistent growth in this sector. Further supporting this trend, the U. S. Centers for Medicare & Medicaid Services added nearly two dozen procedural codes to the Ambulatory Surgical Center covered-procedures list in its final payment rule for 2025, indicating regulatory support for expanded outpatient surgical capabilities.

Segmental Insights

The ablation devices segment is experiencing rapid growth within the Global Interventional Oncology Devices Market. This expansion is primarily driven by the increasing global incidence of various cancers and the growing preference for minimally invasive treatment modalities. Ablation procedures offer significant advantages over conventional surgery, including reduced patient trauma, shorter hospital stays, and faster recovery periods. Furthermore, continuous technological advancements in ablation systems, such as enhanced energy delivery and precise image guidance, contribute to improved treatment efficacy and patient outcomes. These factors collectively bolster the demand for ablation devices as a viable and effective option for targeted tumor destruction.

Regional Insights

North America holds the leading position in the Global Interventional Oncology Devices Market, primarily driven by its highly developed healthcare infrastructure and widespread adoption of advanced medical technologies. The region’s significant cancer prevalence, coupled with a growing preference for minimally invasive treatments, further contributes to this market leadership. A supportive regulatory framework, championed by institutions such as the U. S. Food and Drug Administration (FDA), along with favorable reimbursement policies, encourages innovation and broad market acceptance. This environment, combined with the strong presence of key industry players and a substantial base of skilled interventional oncologists, solidifies North America’s dominance.

Recent Developments

• In October 2025, Intuitive received expanded U.S. Food and Drug Administration (FDA) clearance for new AI and advanced imaging capabilities within its Ion robotic bronchoscopy system. This enhancement integrates artificial intelligence across Ion's entire navigational workflow and introduces advanced imaging like integrated tomosynthesis, enabling real-time imaging updates with a standard 2D C-arm. These advancements support more efficient, accurate, and personalized procedures for lung cancer diagnosis. The Ion system, a robotic-assisted, catheter-based platform, facilitates minimally invasive biopsies deep within the lung, improving the ability to access and sample small, hard-to-reach nodules, thereby advancing interventional oncology for lung cancer.

• In November 2024, Boston Scientific Corporation entered into a definitive agreement to acquire Intera Oncology Inc., a privately held medical device company. This acquisition was aimed at expanding Boston Scientific's interventional oncology offerings by incorporating Intera Oncology's Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug. Both products are approved by the U.S. Food and Drug Administration and are used for hepatic artery infusion (HAI) therapy to treat liver tumors, particularly those caused by metastatic colorectal cancer. This strategic move strengthens Boston Scientific’s portfolio of solutions for both primary and metastatic liver cancer.

• In May 2024, Merit Medical Systems, Inc. announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug and the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia. These new additions expand Merit Medical's embolics portfolio, which is crucial for interventional oncology procedures. The Siege Vascular Plug features a recapturable design for precise placement, achieving vessel occlusion rapidly. The Bearing nsPVA Express offers a prefilled syringe solution, streamlining embolization procedures by eliminating preparation steps. These advancements enhance minimally invasive treatment options for conditions such as blocking blood flow to tumors.

• In May 2024, Siemens Healthineers announced a new 10-year strategic agreement with University Hospitals. Building on a decades-long collaboration, this partnership aims to advance patient care in oncology, cardiovascular, and neurovascular areas. Specifically relevant to the Global Interventional Oncology Devices Market, the agreement includes deploying advanced imaging technologies such as PET/CT scanners at University Hospitals Seidman Cancer Center for improved cancer care and theranostics. Additionally, angiography systems for interventional radiology procedures, including targeted ablations and therapy agent delivery, will be installed, and new magnetic resonance (MR) technologies will be developed to enhance diagnostic and therapeutic capabilities.

Key Market Players

• Medtronic PLC
• Terumo Corporation
• Boston Scientific Corporation
• Merit Medical Systems, Inc.
• HealthTronics, Inc.
• Johnson & Johnson
• Teleflex Inc.
• Angiodynamics Inc.
• MedWaves, Inc.
• Becton, Dickinson, and Company

Report Scope:

In this report, the Global Interventional Oncology Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Interventional Oncology Devices Market, By Product:

o   Embolization Devices

o   Ablation Devices

o   Support Devices

• Interventional Oncology Devices Market, By Procedure:

o   Thermal Tumor Ablation

o   Non-thermal Tumor Ablation

o   Transcatheter Arterial Chemoembolization (TACE)

o   Transcatheter Arterial Radioembolization (TARE)

o   Transcatheter Arterial Embolization (TAE)

• Interventional Oncology Devices Market, By Cancer Type:

o   Liver

o   Kidney

o   Lung

o   Bone

o   Others

• Interventional Oncology Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Interventional Oncology Devices Market.

Available Customizations:

Global Interventional Oncology Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Interventional Oncology Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]